Pricing
  1. JP-listed companies
  2. TAIKO PHARMACEUTICAL CO., LTD.
  3. Financials
  4. Stockholders' equity

TAIKO PHARMACEUTICAL CO., LTD. (4574)

Market cap
¥15.4B
P/E ratio
27.8x
Makes over-the-counter medicines like Seirogan and Cleverin infection control products, serving consumers and institutions across Japan and Asia.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndStockholders' equity (Million JPY)YoY (%)
Dec 31, 20258,518+6.96%
Dec 31, 20247,964+18.18%
Dec 31, 20236,739-16.22%
Dec 31, 20228,044-37.19%
Dec 31, 202112,807-43.78%
Dec 31, 202022,781+17.59%
Mar 31, 202019,374+10.80%
Mar 31, 201917,485+6.49%
Mar 31, 201816,420+6.73%
Mar 31, 201715,385+17.08%
Mar 31, 201613,140+5.34%
Mar 31, 201512,473+9.36%
Mar 31, 201411,406

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat